Trial Profile
One-arm, single-center, open-label clinical study for apatinib combined with capecitabine in the treatment of advanced triple-negative breast cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Rivoceranib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 09 Oct 2018 New trial record